Tvardi Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Sugar Land, TX
TVRD chart
What traders are saying about $TVRD
Latest postsTvardi Therapeutics, Inc. news
- Tvardi Therapeutics (TVRD) Options Chain & Prices 2026 $TVRD
MarketBeat ·
- Tvardi Therapeutics, Inc. Estimates – NASDAQ:TVRD
TradingView ·
- Tvardi Therapeutics (NASDAQ:TVRD) Penny Stock Gains 10% as Liver Cancer Trial Data Draw Closer: What Is Driving It?
kalkine.ca ·
- Chardan Capital Initiates Tvardi Therapeutics(TVRD.US) With Buy Rating, Announces Target Price $8
Moomoo ·
- Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Yahoo Finance ·
- New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
Yahoo Finance ·
- Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Yahoo Finance ·
- Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Yahoo Finance ·
- Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Yahoo Finance ·
- TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Yahoo Finance ·
- Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Yahoo Finance ·
- Tvardi Therapeutics to Participate in Upcoming Investor Events
Yahoo Finance ·
Tvardi Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $7.1M | $21.0M | $41.9M |
| Net income | -$18.2M | -$29.4M | -$11.8M | -$85.5M |
| Diluted EPS | $-3.26 | $-11.42 | $-26.26 | $-19.12 |
| Total assets (year end) | $32.1M | $35.2M | $125.8M | $182.2M |
| Cash and equivalents (year end) | $20.7M | $31.6M | $51.8M | $63.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Tvardi Therapeutics, Inc.
- Ticker
- TVRD (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Sugar Land, TX
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1346830
- Former names
- Cara Therapeutics, Inc., Cara Therapeutics Inc
Frequently asked questions
What exchange is Tvardi Therapeutics, Inc. listed on?
Tvardi Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TVRD.
What industry is Tvardi Therapeutics, Inc. in?
Tvardi Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Tvardi Therapeutics, Inc. headquartered?
Tvardi Therapeutics, Inc.'s business address on file with the SEC is in Sugar Land, TX.
When does Tvardi Therapeutics, Inc.'s fiscal year end?
Tvardi Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Tvardi Therapeutics, Inc. report?
Tvardi Therapeutics, Inc. reported $7.1M in revenue for calendar year 2024, according to its SEC filings.